Profile data is unavailable for this security.
About the company
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
- Revenue in USD (TTM)0.00
- Net income in USD-6.01m
- Incorporated1994
- Employees--
- LocationProtagenic Therapeutics Inc149 FIFTH AVENUE, SUITE 500NEW YORK 10010United StatesUSA
- Phone+1 (212) 994-8200
- Fax+1 (302) 636-5454
- Websitehttps://protagenic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reliv International Inc | 35.13m | -175.48k | 6.35m | 208.00 | -- | 0.9165 | 15.88 | 0.1808 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Theriva Biologics Inc | 0.00 | -19.04m | 6.40m | 21.00 | -- | 0.2025 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 6.46m | 80.00 | -- | 0.6048 | -- | 0.1255 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| NLS Pharmaceutics AG | 0.00 | -15.47m | 6.49m | 2.00 | -- | -- | -- | -- | -0.534 | -0.534 | 0.00 | -0.1322 | 0.00 | -- | -- | 0.00 | -714.74 | -308.05 | -- | -- | -- | -- | -- | -- | -- | -175.42 | -- | -- | -- | -- | -38.08 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -17.46m | 6.51m | 7.00 | -- | 1.18 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Ainos Inc | 122.11k | -13.77m | 6.54m | 46.00 | -- | 0.199 | -- | 53.52 | -3.32 | -3.32 | 0.0298 | 5.23 | 0.0035 | 0.9854 | 1.21 | 2,654.57 | -39.94 | -36.36 | -42.28 | -58.33 | -207.80 | 36.82 | -11,277.18 | -813.63 | 1.72 | -91.59 | 0.1961 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -7.00m | 6.56m | 4.00 | -- | 0.6314 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 6.58m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Integrated BioPharma, Inc. | 50.57m | -116.00k | 6.62m | 141.00 | -- | 0.3502 | 31.24 | 0.131 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 6.65m | -- | -- | 3.12 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 733.87k | -21.24m | 6.69m | 19.00 | -- | 0.5351 | -- | 9.12 | -12.67 | -12.67 | 0.4097 | 4.04 | 0.0406 | -- | 2.37 | 38,624.74 | -117.54 | -79.57 | -130.37 | -83.41 | -- | -- | -2,894.69 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 6.73m | 8.00 | -- | 1.59 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.77m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 6.88m | 8.00 | -- | 0.3463 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 6.95m | 5.00 | -- | 0.1307 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Protagenic Therapeutics Inc's reporting currency: US Dollar USD
2.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 32.00k | 0.72% |
| Geode Capital Management LLCas of 31 Mar 2024 | 25.17k | 0.57% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 21.41k | 0.48% |
| FNY Capital Management LPas of 31 Mar 2024 | 18.75k | 0.42% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.81k | 0.31% |
| Tower Research Capital LLCas of 31 Mar 2024 | 5.81k | 0.13% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 1.17k | 0.03% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 27.00 | 0.00% |
| CWM LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 1.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
